Literature DB >> 33814607

Point-of-Care Measurement of Kaolin Activated Clotting Time during Cardiopulmonary Bypass: A Single Sample Comparison between ACT Plus and i-STAT.

Nousjka P A Vranken1, Amber J A J Theelen1, Tamar Orbons1, Paul J C Barenbrug1, Patrick W Weerwind1.   

Abstract

Heparin anticoagulation monitoring by point-of-care activated clotting time (ACT) is essential for cardiopulmonary bypass (CPB) initiation, maintenance, and anticoagulant reversal. Concerns exist regarding the comparability of kaolin activated ACT devices. The current study, therefore, evaluated the agreement of ACT assays using parallel measurements performed on two commonly used devices. Measurements were conducted in a split-sample fashion on both the ACT Plus (Medtronic, Minneapolis, MN) and i-STAT (Abbott Point of Care, Princeton, NJ) analyzers. Blood samples from 100 adult patients undergoing elective cardiac surgery with CPB were assayed at specified time points: before heparinization, following systemic heparinization, after CPB initiation, every 30 minutes during CPB, and following protamine administration. A cutoff value of 400 seconds (s) was used as part of the local protocol. Measurements were compared using t tests or Wilcoxon signed-rank tests, linear regression, and Bland-Altman analyses. Parallel ACT measurements demonstrated a good linear correlation (r = .831, p < .001). The overall median difference between both measurements was significantly different from zero, amounting to 87 (14-189) (p < .001), with limits of agreement of -124 and 333s. The i-STAT-derived ACT values were systematically lower than the ACT Plus values, which was more pronounced during CPB. Fourteen patients received additional heparin during CPB at a median ACT Plus value of 414s, with a concomitant median i-STAT value of 316s. Assuming 308s as the theoretical i-STAT cutoff value based on the linear regression equation and an ACT Plus threshold of 400s, 29 patients would have received additional heparin. Based on these results, kaolin point-of-care ACT devices cannot be used interchangeably. Device-specific predefined target values are warranted to avert heparin overdosing during CPB. © Copyright 2021 AMSECT.

Entities:  

Keywords:  activated clotting time; cardiopulmonary bypass; threshold value

Year:  2021        PMID: 33814607      PMCID: PMC7995621          DOI: 10.1182/ject-2000046

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  9 in total

1.  Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.

Authors:  S Dalbert; M T Ganter; L Furrer; R Klaghofer; A Zollinger; C K Hofer
Journal:  Acta Anaesthesiol Scand       Date:  2006-04       Impact factor: 2.105

2.  Clinical evaluation of the i-STAT kaolin activated clotting time (ACT) test in different clinical settings in a large academic urban medical center: comparison with the Medtronic ACT Plus.

Authors:  Elizabeth Lee Lewandrowski; Elizabeth M Van Cott; Kimberly Gregory; Ik-Kyung Jang; Kent B Lewandrowski
Journal:  Am J Clin Pathol       Date:  2011-05       Impact factor: 2.493

3.  In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass.

Authors:  R J Huyzen; W van Oeveren; F Wei; P Stellingwerf; P W Boonstra; Y J Gu
Journal:  Ann Thorac Surg       Date:  1996-08       Impact factor: 4.330

4.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

5.  Clinical Evaluation of Measuring the ACT during Elective Cardiac Surgery with Two Different Devices.

Authors:  Florian Falter; Nabeel Razzaq; Martin John; Jens Fassl; Markus Maurer; Sean Ewing; Ross Hofmeyr
Journal:  J Extra Corpor Technol       Date:  2018-03

6.  2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery.

Authors:  Luc Puis; Milan Milojevic; Christa Boer; Filip M J J De Somer; Tomas Gudbjartsson; Jenny van den Goor; Timothy J Jones; Vladimir Lomivorotov; Frank Merkle; Marco Ranucci; Gudrun Kunst; Alexander Wahba
Journal:  Interact Cardiovasc Thorac Surg       Date:  2020-02-01

7.  Anticoagulation management.

Authors:  Blaze W Cook
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

8.  Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings. The i-STAT celite-activated clotting time test.

Authors:  Rita Paniccia; Sandra Fedi; Fiorella Carbonetto; Daniela Noferi; Paolo Conti; Brunella Bandinelli; Betti Giusti; Lucia Evangelisti; Paola Pretelli; Mara F G Palmarini; Rosanna Abbate; Domenico Prisco
Journal:  Anesthesiology       Date:  2003-07       Impact factor: 7.892

9.  Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability.

Authors:  Daniel Dirkmann; Elisabeth Nagy; Martin W Britten; Jürgen Peters
Journal:  BMC Anesthesiol       Date:  2019-09-06       Impact factor: 2.217

  9 in total
  2 in total

1.  Can the Minimum Protamine Dose to Neutralize Heparin at the Completion of Cardiopulmonary Bypass be Significantly Lower than the Conventional Practice?

Authors:  Min-Ho Lee; William Riley; Kenneth G Shann
Journal:  J Extra Corpor Technol       Date:  2021-09

Review 2.  Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?

Authors:  Michael Hardy; Jonathan Douxfils; Anne-Sophie Dincq; Anne-Laure Sennesael; Olivier Xhaet; Francois Mullier; Sarah Lessire
Journal:  Front Cardiovasc Med       Date:  2022-03-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.